Journal: American Journal of Translational Research

Article Title: Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo

doi:

Figure Lengend Snippet: CD3+CD8+ T cell-mediated cytotoxicity was measured by flow cytometry. A. For H22 cells, the cytotoxicity in the LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. B. Statistical chart of target cell H22 specific lysis (%) in each group under different effector-target ratios. C. For Hep1-6 cells, the cytotoxicity in LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. D. Statistical chart of target cell Hep1-6 specific lysis (%) in each group under different effector-target ratios. These results indicate that LV-SMP30 transduced DCs enhances the CD3+CD8+ T cell-mediated specific cytotoxicity against H22 cells.

Article Snippet: Mouse liver cancer cell lines H22 and Hep1-6 were employed, purchased from iCell Bioscience Inc.

Techniques: Flow Cytometry, Lysis

Journal: American Journal of Translational Research

Article Title: Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo

doi:

Figure Lengend Snippet: Construction of BALB/c nude mouse models of subcutaneous xenografts. A. BALB/c nude mice with equal-sized (~100 mm3) single H22 tumors were treated with CD3+CD8+ T cells. B. Recording chart of tumor growth process. C. Tumor volume on day 15: PBS group, Untreated group, LV group, Protein group, LV-SMP30 group (from left to right). D. Tumors harvested from mice on day 15: PBS group, Untreated group, LV group, Protein group, LV-SMP30 group (from left to right). E. Tumor growth curve. These results demonstrated that the tumor volume in the LV-SMP30 group was smaller than that of other control groups (P<0.05).

Article Snippet: Mouse liver cancer cell lines H22 and Hep1-6 were employed, purchased from iCell Bioscience Inc.

Techniques: Control

Journal: Advanced Science

Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

doi: 10.1002/advs.202105631

Figure Lengend Snippet: Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.

Article Snippet: H22 mouse liver cancer cell‐specific neoantigen (sequence: HTDAHAQAFAALFDSMH) was obtained from GenScript USA Inc.

Techniques: Immunopeptidomics, In Silico, Enzyme-linked Immunospot, Vaccines, Activation Assay

Journal: Advanced Science

Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

doi: 10.1002/advs.202105631

Figure Lengend Snippet: Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.

Article Snippet: H22 mouse liver cancer cell‐specific neoantigen (sequence: HTDAHAQAFAALFDSMH) was obtained from GenScript USA Inc.

Techniques: Vaccines, Generated, Irradiation, Control, Incubation, Staining, Zeta Potential Analyzer, Membrane, SDS Page, Western Blot